SHANGHAI, China, Feb. 8 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, is proud to announce that it was selected for the Deloitte Technology Fast 500 Asia Pacific 2008 list for the fifth consecutive year. The Deloitte program recognizes technology companies in the Asia Pacific region that have achieved the fastest rates of annual revenue growth during the past three years. WuXi PharmaTech is one of only 13 companies to be so recognized for five years in a row and the only such company in China.
"Achieving our place in this ranking of Asia Pacific's elite growth companies is recognition of our successful business model," commented Mr. Benson Tsang, Chief Financial Officer of WuXi PharmaTech. "Our business is built around an intense focus on meeting the needs of our biopharmaceutical and medical device partners to improve R&D productivity. We are continuing to make steady progress in expanding our service portfolio to provide a global, fully integrated, high-quality R&D service platform. Our ongoing work to begin GLP toxicology operations in Suzhou, in what will be the largest such facility in China, and to integrate WuXi operations with those of U.S.-based AppTec Laboratory Services, Inc., represent important milestones in that effort."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
For more information, please contact: Ronald Aldridge Director of Investor Relations WuXi PharmaTech (Cayman) Inc. Tel: +1-215-218-5515 Email: firstname.lastname@example.org
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved